Key Highlights
- LeMaitre Vascular shares closed down 25% at $79.
- Q2 FY2026 net sales grew 10% to $70.4 million.
- EPS climbed 23% to $0.74, with gross margin reaching 72.1%.
- The company issued full-year 2026 guidance of $274.3-$278.3 million in revenue and EPS of $2.84-$2.94.
LeMaitre Vascular (NASDAQ: LMAT) shares closed down 25% at $79 despite the company reporting Q2 FY2026 net sales growth of 10% to $70.4 million, with EPS climbing 23% to $0.74.
What Happened
Gross margin reached 72.1%, behind a 34% increase in Artegraft sales, and the company provided full-year 2026 guidance, projecting revenue between $274.3 million and $278.3 million alongside EPS of $2.84 to $2.94.
Market Reaction
Shares fell sharply despite the reported sales and EPS growth, a decline that stands in contrast to the generally constructive underlying results, including the strong Artegraft sales growth and margin expansion.
Outlook
The disclosed information does not specify a reason for the decline; investors are likely to watch for further detail on whether the full-year 2026 guidance range fell short of prior market expectations.
Why did LeMaitre Vascular shares fall 25% despite growth in sales and EPS?
The disclosed information does not specify a reason for the decline beyond the reported results and guidance.
What drove LeMaitre Vascular's gross margin performance?
A 34% increase in Artegraft sales supported gross margin of 72.1%.
What is LeMaitre Vascular's full-year 2026 guidance?
Revenue of $274.3 million to $278.3 million and EPS of $2.84 to $2.94.


_11_19_2026_08_23_11_186799.jpg)



Please wait processing your request...